Flow cytometric measurement of cellular FLICE-inhibitory protein (c-FLIP) in ovarian carcinoma effusions

Cytopathology

Volumn 22, Issue 6, 2011, Pages 373-382

  Dong, H P ^a   Ree Rosnes, A K ^a   Bock, A J ^a   Holth, A ^a   Florenes V A ^a   Trope', C G ^a,b   Risberg, B ^a   Davidson, B ^a,b  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

Author keywords

Apoptosis; C FLIP; Cytology specimens; Flow cytometry; Ovarian carcinoma; Serous effusions

Indexed keywords

CASPASE 3; FLICE INHIBITORY PROTEIN;

ADULT; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL SURVIVAL; EFFUSION; FEMALE; FLOW CYTOMETRY; HUMAN; MAJOR CLINICAL STUDY; OVARY CARCINOMA; PATHOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL NOISE RATIO; WESTERN BLOTTING;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; APOPTOSIS; CASP8 AND FADD-LIKE APOPTOSIS REGULATING PROTEIN; CASPASE 3; EXUDATES AND TRANSUDATES; FEMALE; FLOW CYTOMETRY; HUMANS; METHODS; MIDDLE AGED; OVARIAN NEOPLASMS; PLEURAL EFFUSION; SURVIVAL ANALYSIS; TUMOR CELLS, CULTURED;

EID: 81355138272     PISSN: 09565507     EISSN: 13652303     Source Type: Journal    
DOI: 10.1111/j.1365-2303.2011.00929.x     Document Type: Article

References (42)

1. Vermeulen K, Van bockstaele DR, Berneman ZN. Apoptosis: mechanisms and relevance in cancer. Ann Hematol 2005;84:627-39.
2. Fadeel B, Orrenius S. Apoptosis: a basic biological phenomenon with wide-ranging implications in human disease. J Intern Med 2005;258:479-517.
3. Thompson CB. Apoptosis in the pathogenesis and treatment of disease. Science 1995;267:1456-62.
4. Viktorsson K, Lewensohn R, Zhivotovsky B. Apoptotic pathways and therapy resistance in human malignancies. Adv Cancer Res 2005;94:143-96.
5. Jin Z, El-Deiry WS. Overview of cell death signaling pathways. Cancer Biol Ther 2005;4:139-63.
6. Johnstone RW, Ruefli AA, Lowe SW. Apoptosis: a link between cancer genetics and chemotherapy. Cell 2002;108:153-64.
7. Irmler M, Thome M, Hahne M et al. Inhibition of death receptor signals by cellular FLIP. Nature 1997;388:190-5.
8. Scaffidi C, Schmitz I, Krammer PH, Peter ME. The role of c-FLIP in modulation of CD95-induced apoptosis. J Biol Chem 1999;274:1541-8.
9. Bagnoli M, Canevari S, Mezzanzanica D. Cellular FLICE-inhibitory protein (c-FLIP) signalling: a key regulator of receptor-mediated apoptosis in physiologic context and in cancer. Int J Biochem Cell Biol 2010;42:210-3.
10. Krueger A, Schmitz I, Baumann S, Krammer PH, Kirchhoff S. Cellular FLICE-inhibitory protein splice variants inhibit different steps of caspase-8 activation at the CD95 death-inducing signaling complex. J Biol Chem 2001;276:20633-40.
11. Budd RC, Yeh WC, Tschopp J. cFLIP regulation of lymphocyte activation and development. Nat Rev Immunol 2006;6:196-204.
12. Park SM, Schickel R, Peter ME. Nonapoptotic functions of FADD-binding death receptors and their signaling molecules. Curr Opin Cell Biol 2005;17:610-6.
13. Lamkanfi M, Festjens N, Declercq W, Vanden Berghe T, Vandenabeele P. Caspases in cell survival, proliferation and differentiation. Cell Death Differ 2007;14:44-55.
14. Kataoka T, Budd RC, Holler N et al. The caspase-8 inhibitor FLIP promotes activation of NF-kappaB and Erk signaling pathways. Curr Biol 2000;10:640-8.
15. Chawla-Sarkar M, Bae SI, Reu FJ et al. Downregulation of Bcl-2, FLIP or IAPs (XIAP and survivin) by siRNAs sensitizes resistant melanoma cells to Apo2L/TRAIL-induced apoptosis. Cell Death Differ 2004;11:915-23.
16. Ullenhag GJ, Mukherjee A, Watson NF et al. Overexpression of FLIPL is an independent marker of poor prognosis in colorectal cancer patients. Clin Cancer Res 2007;13:5070-5.
17. Korkolopoulou P, Saetta AA, Levidou G et al. c-FLIP expression in colorectal carcinomas: association with Fas/FasL expression and prognostic implications. Histopathology 2007;51:150-6.
18. Mori T, Doi R, Toyoda E et al. Regulation of the resistance to TRAIL-induced apoptosis as a new strategy for pancreatic cancer. Surgery 2005;138:450-5.
19. Murtaza I, Saleem M, Adhami VM, Hafeez BB, Mukhtar H. Suppression of cFLIP by lupeol, a dietary triterpene, is sufficient to overcome resistance to TRAIL-mediated apoptosis in chemoresistant human pancreatic cancer cells. Cancer Res 2009;69:1156-65.
20. Rogers KM, Thomas M, Galligan L et al. Cellular FLICE-inhibitory protein regulates chemotherapy-induced apoptosis in breast cancer cells. Mol Cancer Ther 2007;6:1544-51.
21. El-Gazzar A, Wittinger M, Perco P et al. The role of c-FLIP(L) in ovarian cancer: chaperoning tumor cells from immunosurveillance and increasing their invasive potential. Gynecol Oncol 2010;117:451-9.
22. Horak P, Pils D, Kaider A et al. Perturbation of the tumor necrosis factor - related apoptosis-inducing ligand cascade in ovarian cancer: overexpression of FLIPL and deregulation of the functional receptors DR4 and DR5. Clin Cancer Res 2005;11:8585-91.
23. Clarke P, Tyler KL. Down-regulation of cFLIP following reovirus infection sensitizes human ovarian cancer cells to TRAIL-induced apoptosis. Apoptosis 2007;12:211-23.
24. Mezzanzanica D, Balladore E, Turatti F et al. CD95-mediated apoptosis is impaired at receptor level by cellular FLICE-inhibitory protein (long form) in wild-type p53 human ovarian carcinoma. Clin Cancer Res 2004;10:5202-14.
25. Abedini MR, Qiu Q, Yan X, Tsang BK. Possible role of FLICE-like inhibitory protein (FLIP) in chemoresistant ovarian cancer cells in vitro. Oncogene 2004;23:6997-7004.
26. MacFarlane M, Harper N, Snowden RT et al. Mechanisms of resistance to TRAIL-induced apoptosis in primary B cell chronic lymphocytic leukaemia. Oncogene 2002;21:6809-18.
27. Valente G, Manfroi F, Peracchio C et al. cFLIP expression correlates with tumour progression and patient outcome in non-Hodgkin lymphomas of low grade of malignancy. Br J Haematol 2006;132:560-70.
28. Kamsteeg M, Rutherford T, Sapi E et al. Phenoxodiol - an isoflavone analog - induces apoptosis in chemoresistant ovarian cancer cells. Oncogene 2003;22:2611-20.
29. Lane D, Cartier A, L'Espérance S et al. Differential induction of apoptosis by tumor necrosis factor-related apoptosis-inducing ligand in human ovarian carcinoma cells. Gynecol Oncol 2004;93:594-604.
30. Dong HP, Kleinberg L, Silins I et al. Death receptor expression is associated with poor response to chemotherapy and shorter survival in metastatic ovarian carcinoma. Cancer 2008;112:84-93.
31. Kleinberg L, Dong HP, Holth A et al. Cleaved caspases and NF-κB p65 are prognostic factors in metastatic ovarian carcinoma. Hum Pathol 2009;40:795-806.
32. Dong HP, Holth A, Berner A, Davidson B, Risberg B. Flow cytometric immunphenotyping of epithelial cancer cells in effusions - technical considerations and pitfalls. Cytometry B Clin Cytom 2007;72B:332-43.
33. Dong HP, Kleinberg L, Davidson B, Risberg B. Methods for simultaneous measurement of apoptosis and cell surface phenotype of epithelial cells in effusions by flow cytometry. Nat Protoc 2008;3:955-64.
34. Shankey TV, Cobb J, Scibelli P et al. Measurement of ZAP-70 expression in CLL using an optimized flow cytometric assay for ZAP-70 protein levels in whole blood samples. Miami, FL: Beckman Coulter, Inc. Available at
35. Dong HP, Holth A, Kleinberg L et al. Evaluation of cell surface expression of phosphatidylserine in ovarian carcinoma effusions using the Annexin-V/7-AAD assay - clinical relevance and comparison to other apoptosis parameters. Am J Clin Pathol 2009;132:756-62.
36. Koester SK, Bolton WE. Strategies for cell permeabilization and fixation in detecting surface and intracellular antigens. Methods Cell Biol 2001;63:253-68.
37. Stewart CC, Stewart SJ. Titering antibodies. Curr Protoc Cytom 2001;Chapter 4:Unit 4.1.
38. Hulspas R. Titration of fluorochrome-conjugated antibodies for labeling cell surface markers on live cells. Curr Protoc Cytom 2010;Chapter 6:Unit 6.29.
39. Lanza F, Latorraca A, Moretti S et al. Comparative analysis of different permeabilization methods for the flow cytometry measurement of cytoplasmic myeloperoxidase and lysozyme in normal and leukemic cells. Cytometry 1997;30:134-44.
40. Macey MG, McCarthy DA, Milne T, Cavenagh JD, Newland AC. Comparative study of five commercial reagents for preparing normal and leukaemic lymphocytes for immunophenotypic analysis by flow cytometry. Cytometry 1999;38:153-60.
41. Duiker EW, van der Zee AG, de Graeff P et al. The extrinsic apoptosis pathway and its prognostic impact in ovarian cancer. Gynecol Oncol 2010;116:549-55.
42. Bagnoli M, Ambrogi F, Pilotti S et al. c-FLIPL expression defines two ovarian cancer patient subsets and is a prognostic factor of adverse outcome. Endocr Relat Cancer 2009;16:443-53.